Max Mousseron Institute for Biomolecules, UMR CNRS 5247, Group Research Center for Artificial Biopolymers, University Montpellier 1, CNRS, Faculty of Pharmacy, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France.
Macromol Biosci. 2011 Dec 8;11(12):1653-61. doi: 10.1002/mabi.201100224. Epub 2011 Nov 3.
Man-made artificial organic polymers are among the more recent sources of materials used by humans. In medicine, they contribute to applications in surgery, dentistry and pharmacology. Nowadays, innovations in the field of therapeutic polymers rely on novel polymers for specific applications such as guided tissue regeneration, tissue engineering, drug delivery systems, gene transfection, etc. Introducing reactive chemical functions within or along polymer backbones is an attractive route to generate functional polymers for medicine. However, any candidate to effective application must fulfil a number of requirements, grouped under the terms biocompatibility and biofunctionality, to be of real interest and have a future for effective application. Whenever the application requires a therapeutic aid for a limited period of time to help natural healing, bioresorbability is to be taken into account on top of biocompatibility and biofunctionality. This contribution presents the case of "artificial biopolymers" and discusses the potential of some members of the family with respect to temporary therapeutic applications that require functional polymers.
人造有机聚合物是人类最近使用的材料来源之一。在医学领域,它们被应用于手术、牙科和药理学。如今,治疗性聚合物领域的创新依赖于特定应用的新型聚合物,如引导组织再生、组织工程、药物输送系统、基因转染等。在聚合物主链内或沿聚合物主链引入反应性化学官能团是生成用于医学的功能性聚合物的一种有吸引力的方法。然而,任何有希望实际应用的候选物都必须满足一些要求,这些要求被归类为生物相容性和生物功能性,以具有真正的应用价值和未来。只要应用需要在有限的时间内提供治疗辅助以帮助自然愈合,除了生物相容性和生物功能性之外,还需要考虑生物可吸收性。本贡献介绍了“人工生物聚合物”的情况,并讨论了该家族某些成员在需要功能性聚合物的临时治疗应用方面的潜力。